ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Inovio reports positive data from Phase II Covid-19 DNA vaccine trial pharmaceutical-technology
May 12, 2021The Inovio vaccine Phase II trial assessed the safety, tolerability and immunogenicity of two doses of INO-4800 to detect optimal dose(s) for age groups, namely 18 to 50 years and 51 years and above, for the Phase III efficacy analysis.
Pharma Sources Insight January 2025
